HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

Abstract Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Format: Artigo
Idioma:Inglês
Publicat: Nature Portfolio 2022-05-01
Col·lecció:npj Breast Cancer
Accés en línia:https://doi.org/10.1038/s41523-022-00434-w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars